Fundraising Fox

Milenko Cicmil

Investor

Partner at Cure Ventures

Boston, Massachusetts

Writes $100K – $5M checks · typically $1.5M

About

Associated with portfolio company Tasca Therapeutics, which works on post-translational modification to expand the druggable proteome.

Experience

  1. University of ReadingVisiting Research Fellow at Univ. of Reading, UKcurrent2020 — presentUnited Kingdom
  2. Cure VenturesPartnercurrent2021 — presentUnited States
  3. AMP DiscoveryChairman Of The Board AMP Discovery2021 — 2022
  4. IpsenVice President Global Head of external Innovation2019 — 2021Cambridge, Massachusetts, USA
  5. FogPharmaVice President - Translational Biology2017 — 2019Cambridge, USA
  6. MerckDirector at Merck Innovation Hub2016 — 2017Cambridge USA
  7. MerckDirector Pharmacology Immuno-Oncology and Immunomodulation2013 — 2016Greater Boston Area
  8. MerckDirector In vivo Pharmacology R&I2011 — 2013Boston, US
  9. AstraZenecaGroup Leader Integrative Pharmacology Discovery Bioscience - Inflammation2007 — 2011Leicester, United Kingdom
  10. AstraZenecaSenior Research Scientist2004 — 2007Leicester, United Kingdom
  11. GE HealthcareSenior Research Scientist2002 — 2004Amersham UK
  12. Cancer Research UKTranslational Science - Research Fellow2000 — 2002London, United Kingdom

Education

  1. King's College LondonBachelor’s Degree, Cell/Cellular and Molecular Biology1994 — 1997
  2. University of ReadingDoctor of Philosophy (Ph.D.), Molecular Pharmacology1997 — 2000

Skills & more

Biochemistry5Biomarker Discovery7Biomarkers7Biotechnology5CRO3Cell Culture3Clinical Development6DMPK2Drug Design4Drug Development14Drug Discovery25In Vitro7
+6 moreIn VivoLead ChangeLifesciencesPharmaceutical IndustryPharmacologyTarget Identification

From Milenko's professional profile.

Same school

Shared employers

Colleagues at Cure Ventures